Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
- Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches.J Am Acad Dermatol. 2015; 72: 929-941
- Screening, early detection, education, and trends for melanoma: Current status (2007-2013) and future directions. Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology.J Am Acad Dermatol. 2014; 71: 599.e1-12
- Dermoscopic diagnosis by a trained clinician vs. a clinician with minimal dermoscopy training vs. computer-aided diagnosis of 341 pigmented skin lesions: a comparative study.Br J Dermatol. 2002; 147: 481-486
- The evolution of melanoma diagnosis: 25 years beyond the ABCDs.CA Cancer J Clin. 2010; 60: 301-316
- Handbook on dermoscopy: a color wheel approach.1st edition. Lippincott Williams & Wilkins, Philadelphia2016
- Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions.Arch Dermatol. 2005; 141: 1008-1014
- Risk-stratified screening for detection of melanoma.JAMA. 2015; 313: 616-617
- Modern diagnostic procedures in dermatological oncology.Pathologe. 2015; 36: 11-15
- Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center.J Am Acad Dermatol. 2010; 62: 751-756
- Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting.Br J Dermatol. 2008; 159: 669-676
- Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas.JAMA Dermatol. 2014; 150: 1306-1314
- Limitations of dermoscopy in the recognition of melanoma.Arch Dermatol. 2005; 141: 155-160
- Pitfalls in the dermoscopic diagnosis of amelanotic melanoma.J Am Acad Dermatol. 2015; 72: S2-S3
- Automatic differentiation of melanoma and melanocytic nevi with multispectral digital dermoscopy: a feasibility study.J Am Acad Dermatol. 2001; 44: 207-218
- The performance of MelaFind: a prospective multicenter study.Arch Dermatol. 2011; 147: 188-194
Winkelmann RR, Tucker N, White R, et al. Evaluating diagnostic enhancement with multi-spectral digital skin lesion analysis: a meta-analysis of 5 studies. Poster presentation: Winter Clinical Dermatology Conference. Kaanapali (HI), January 16–21, 2014.
- Negative predictive value of pigmented lesion evaluation by multispectral digital skin lesion analysis in a community practice setting.J Clin Aesthet Dermatol. 2015; 8: 20-22
- Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy (CSLM).Arch Dermatol. 2001; 137: 923-929
- Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivo.J Am Acad Dermatol. 2001; 45: 365-376
- Melanoma or pigmented basal cell carcinoma: a clinical-pathologic correlation with dermoscopy, in vivo confocal scanning laser microscopy, and routine histology.Skin Res Technol. 2002; 8: 282-287
- Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions.Dermatol Pract Concept. 2013; 3: 19-27
- Reflectance confocal microscopy as a second-level examination in skin oncology improves diagnostic accuracy and saves unnecessary excisions: a longitudinal prospective study.Br J Dermatol. 2014; 171: 1044-1051
- In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions.J Invest Dermatol. 2009; 129: 131-138
- Expert review remains important in the histological diagnosis of cutaneous melanocytic lesions.Histopathology. 2008; 52: 139-146
- Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party.J Pathol. 1997; 182: 266-272
- Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists.Hum Pathol. 1996; 27: 528-531
- Principles of molecular diagnostics and personalized cancer medicine.in: Chapter 34: immunohistochemical and molecular diagnosis of melanoma. 1st edition. Lippincott Williams & Winkins, Philadelphia2013: 434-450
- Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors.Am J Clin Pathol. 2010; 133: 370-379
- Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.J Cutan Pathol. 2012; 39: 1062-1074
- Cytogenetic and mutational analyses of melanocytic tumors.Dermatol Clin. 2012; 30: 555-566
Neogenomics, Inc NeoSITE™ Melanoma: next-Generation FISH analysis for ambiguous melanocytic lesions. Available at: http://www.neogenomics.com/neosite-melanoma.htm. Accessed June 18, 2015.
- Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses.Am J Surg Pathol. 2013; 37: 1783-1796
- A proposal for improving multicolor FISH sensitivity in the diagnosis of malignant melanoma using new combined criteria.Am J Dermatopathol. 2012; 34: 580-585
- Correlation between histologic assessment and fluorescence in situ hybridization using MelanoSITE in evaluation of histologically ambiguous melanocytic lesions.Arch Pathol Lab Med. 2012; 136: 1671-1679
- Chromosomal copy number analysis in melanoma diagnostics.Methods Mol Biol. 2014; 1102: 199-226
- Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms.Int J Clin Exp Pathol. 2010; 3: 593-599
- Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.J Cutan Pathol. 2015; 42: 244-252
Clarke LE, Berking C, Tahan S, et al. Development of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. Poster presentation: Society for Melanoma Research International Congress. Philadelphia, November 17–19, 2013.
Clarke LE, Bess E, Kolquist K, et al. A clinically validated gene expression score impacts diagnosis and management recommendations of melanocytic lesions by dermatopathologists. Poster presentation: College of American Pathologists Meeting. Chicago, September 7–10, 2014.
- Gene expression profile of primary cutaneous melanomas to distinguish between low and high risk of metastasis.J Clin Oncol. 2013; 31: s9022
- Development of a prognostic genetic signature to predict the metastatic risk associated with melanoma.Clin Cancer Res. 2015; 21: 175-181
- Gene expression profiling for molecular staging of cutaneous melanoma in patients with sentinel lymph node biopsy.J Am Acad Dermatol. 2015; 72: 780-785.e3
- Summary of dermatologist assessment and management of dysplastic nevi: a follow-up survey.J Am Acad Dermatol. 2015; 73: 27-29
Oxford Center for Evidence Based Medicine. Available at: http://www.cebm.net/index.aspx?o=5653. Accessed December 20, 2016.
- Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.J Eur Acad Dermatol Venereol. 2014; 28s5: 3-12
- Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer.J Clin Oncol. 2006; 24: 1877-1882
- Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry.Dermatology. 2002; 205: 362-366
- Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm.Br J Dermatol. 2006; 155: 570-573
- Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions.Melanoma Res. 1994; 4: 391-394
- The dermoscopic versus the clinical diagnosis of melanoma.Eur J Dermatol. 1999; 9: 470-476
- First experiences using reflectance confocal microscopy on equivocal skin lesions in Queensland.Australas J Dermatol. 2011; 52: 89-97
- The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face.J Invest Dermatol. 2010; 130: 2080-2091
- The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions.J Invest Dermatol. 2007; 127: 2759-2765
- The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: A prospective study.Dermatology. 2007; 215: 365-372
- Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008.Am J Surg Pathol. 2010; 34: 314-326
- Immunohistochemical characteristics of melanoma.J Cutan Pathol. 2008; 35: 433-444
- Classifying melanocytic tumors based on DNA copy number changes.Am J Pathol. 2003; 163: 1765-1770
- A genome-wide high resolution array CGH analysis of cutaneous melanoma and comparison of aCGH to FISH in diagnostic evaluation.J Mol Diagn. 2013; 15: 581-591
- Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma.Am J Surg Pathol. 2009; 33: 1146-1156
- Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up.Mod Pathol. 2010; 23: 413-419
- Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases.Mod Pathol. 2011; 24: 613
- The Delphi technique: making sense of consensus.Practical Assessment, Research & Evaluation. 2007; 12: 1-8
- The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology.J Am Acad Dermatol. 2015; 72: 345-348
- Early detection of malignant melanoma: the role of physician examination and self-examination of the skin.CA Cancer J Clin. 1985; 35: 130-151
- The rationale of the ABCDs of early melanoma.J Am Acad Dermatol. 1993; 29: 1060-1061
- Thickness of malignant melanoma: global analysis of related factors.J Dermatol Surg Oncol. 1987; 13 (401–20): 345-390
- Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.JAMA. 2004; 292: 2771-2776
- The “ugly duckling” sign: agreement between observers.Arch Dermatol. 2008; 144: 58-64
- Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches.J Am Acad Dermatol. 2015; 72: 943-958
Relevant Conflicts of Interest: Dr R.R. Winkelmann: fellowship funded in part by grant from Strata Skin Sciences Inc; Dr A.S. Farberg: fellowship funded in part by grant from Strata Skin Sciences Inc, consultant to Castle Biosciences Inc; Dr A.M. Glazer: participated in a research fellowship which was partially funded by Castle Biosciences Inc; Dr A.J. Sober: P.I for phase 4 Strata Skin Sciences Inc Trial; Dr C.J. Cockerell: consultant to Strata Skin Sciences Inc, Castle Biosciences Inc, and Myriad Genetics; Dr D.M. Siegel: member, Board of Directors, Caliber I.D.; Clinical Advisory Board, Michelson Diagnostics, LTD, and Advisory Board attendee for Castle Biosciences Inc; Dr S.A. Leachman: Myriad Genetics Laboratory Medical & Scientific Advisory Board member; Dr W.A. High: None; Dr O. Markowitz: consultant for 3-Gen, Michelson Diagnostics Ltd, and Strata Skin Sciences Inc; Dr B. Berman: None; Dr D.M. Pariser: Advisory Board attendee for Castle Biosciences Inc; Dr G. Goldenberg: consultant to Strata Skin Sciences Inc; Dr T. Rosen: Advisory Board attendee for Castle Biosciences Inc; and Dr D.S. Rigel: served as chief medical advisor to Strata Skin Sciences Inc, consultant to Castle Biosciences Inc.